HPTN 104 – Dual Prevention Pill (DPP) Study

HPTN 104 Study, a Phase 2b, open-label, multisite trial comparing adherence to a single daily Dual Prevention Pill (DPP) versus a two-pill regimen (2PR) for pre-exposure prophylaxis (PrEP) and pregnancy prevention (separately administered PrEP and COC) in people of childbearing potential without HIV.

Study Details:

• Objective: Assess adherence to DPP vs. 2PR for HIV and pregnancy prevention
• Tagert Group: Individuals aged 16 – 39 years
• Duration: Approximately 48 weeks per participant
• Study Sites: Around 4 locations in sub-Saharan Africa
• Commencement Date: April – May 2025
• Sponsors: Division of AIDS (DAIDS), U.S. NIAID, and NIH

Latest Update

March 2025

For more information about HPTN 104 Study, please email rhicomms@wrhi.ac.za.